Literature DB >> 23380709

Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients.

L E Roeker1, D R Larson, R A Kyle, S Kumar, A Dispenzieri, S V Rajkumar.   

Abstract

The purpose of this study was to determine if there is an increased risk of acute leukemia and myelodysplastic syndromes (MDS) in persons with monoclonal gammopathy of undetermined significance (MGUS). We used a large population-based cohort of individuals systematically screened for the presence or absence of MGUS. MGUS status was then linked to the diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and MDS. A total of 17 315 patients age 50 and older (605 MGUS and 16 710 controls) with a cumulative 435 021 person-years of follow-up were studied. MGUS patients had a significantly higher risk of developing MDS compared with controls, hazard ratio 2.4 (95% CI 1.08, 5.32), P=0.031. There was no statistically significant increase in the risk of AML (RR 1.36 P=0.675), and no increased risk of developing ALL.

Entities:  

Mesh：

Year:  2013        PMID： 23380709      PMCID： PMC3676476          DOI： 10.1038/leu.2013.34

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  16 in total

Review 1.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

2.  Multiple myeloma and acute myelomonocytic leukemia.

Authors:  R A Kyle; R V Pierre; E D Bayrd
Journal:  N Engl J Med       Date:  1970-11-19       Impact factor: 91.245

3.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

4.  The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia.

Authors:  D E Bergsagel; A J Bailey; G R Langley; R N MacDonald; D F White; A B Miller
Journal:  N Engl J Med       Date:  1979-10-04       Impact factor: 91.245

5.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

8.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Authors:  Antonio Palumbo; Roman Hajek; Michel Delforge; Martin Kropff; Maria Teresa Petrucci; John Catalano; Heinz Gisslinger; Wiesław Wiktor-Jędrzejczak; Mamia Zodelava; Katja Weisel; Nicola Cascavilla; Genadi Iosava; Michele Cavo; Janusz Kloczko; Joan Bladé; Meral Beksac; Ivan Spicka; Torben Plesner; Joergen Radke; Christian Langer; Dina Ben Yehuda; Alessandro Corso; Lindsay Herbein; Zhinuan Yu; Jay Mei; Christian Jacques; Meletios A Dimopoulos
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

9.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

10.  A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults.

Authors:  J Cuzick; S Erskine; D Edelman; D A Galton
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640
View more
  15 in total

1.  Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases.

Authors:  Yataro Yoshida; Shigeru Oguma; Hitoshi Ohno; Yukiharu Nakabo; Tatsuya Katsurada; Masahiro Kawahara; Hiroshi Kawabata
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

Review 2.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

3.  Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations.

Authors:  S Matarraz; B Paiva; M Díez-Campelo; S Bárrena; M Jara-Acevedo; M L Gutiérrez; J M Sayagués; M-L Sánchez; P Bárcena; M P Garrastazul; M J Berruezo; J M Duran; C Cerveró; J A García-Erce; L Florensa; G D Méndez; O Gutierrez; M C Del Cañizo; J J M van Dongen; J F San Miguel; A Orfao
Journal:  Leukemia       Date:  2014-03-14       Impact factor: 11.528

Review 4.  Update on second primary malignancies in multiple myeloma: a focused review.

Authors:  O Landgren; S Mailankody
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

5.  New cancers after autotransplantations for multiple myeloma.

Authors:  Anuj Mahindra; Girindra Raval; Paulette Mehta; Ruta Brazauskas; Mei-Jie Zhang; Xiaobo Zhong; Jennifer M Bird; César O Freytes; Gregory A Hale; Roger Herzig; Leona A Holmberg; Rammurti T Kamble; Shaji Kumar; Hillard M Lazarus; Navneet S Majhail; David I Marks; Jan S Moreb; Richard Olsson; Wael Saber; Bipin N Savani; Gary J Schiller; Jason Tay; Dan T Vogl; Edmund K Waller; Peter H Wiernik; Baldeep Wirk; Sagar Lonial; Amrita Y Krishnan; Angela Dispenzieri; Nancy A Brandenburg; Robert Peter Gale; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-31       Impact factor: 5.742

6.  Identifying monoclonal gammopathy of undetermined significance in electronic health data.

Authors:  Mara Meyer Epstein; Cassandra Saphirak; Yanhua Zhou; Candace LeBlanc; Alan G Rosmarin; Arlene Ash; Sonal Singh; Kimberly Fisher; Brenda M Birmann; Jerry H Gurwitz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-11-17       Impact factor: 2.890

7.  Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; T McKee; I Dunand-Sauthier; B Manfroi; S Park; J Passweg; B Huard
Journal:  Leukemia       Date:  2015-03-10       Impact factor: 11.528

8.  Characterization of monoclonal gammopathy of undetermined significance by calorimetric analysis of blood serum proteome.

Authors:  Francisca Barceló; Joan J Cerdà; Antonio Gutiérrez; Teresa Jimenez-Marco; M Antonia Durán; Andrés Novo; Teresa Ros; Antonia Sampol; José Portugal
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

9.  Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura.

Authors:  Masao Hagihara; Morihiro Inoue; Kenichiro Kodama; Tomoyuki Uchida; Jian Hua
Journal:  Case Rep Hematol       Date:  2016-08-14

10.  Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.

Authors:  S Ailawadhi; A Swaika; P Razavi; D Yang; A Chanan-Khan
Journal:  Blood Cancer J       Date:  2014-09-05       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.